Enhancement of oxaliplatin efficacy and amelioration of intestinal epithelial damage by

Background: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide, necessitating extensive research into effective treatment strategies. Despite advancements in targeted therapies and immunotherapies, traditional chemotherapy remains the primary treatment modality for most patients. Here, we explored the synergy between Methods: We utilized a BALB/c nude mouse subcutaneous tumor model to assess the therapeutic impacts of LGG and Oxp. Mice were randomized into five groups: negative control, model control, Oxp, LGG, and LGG + Oxp treatment groups. The main outcomes assessed included tumor weight and volume, histopathological changes, and gene expression via qRT-PCR. The gut microbiota composition was examined by 16s rRNA gene sequencing. Results: The combined treatment of LGG and Oxp significantly reduced tumor weight and volume, and improved tumor-associated pathological changes compared to the model group. The LGG treatment also alleviated Oxp-induced intestinal damage and inflammation, maintaining intestinal barrier integrity. The combined treatment modulated genes linked to intestinal barrier function and inflammation, upregulated Conclusion: The combined use of LGG and Oxp offers a promising therapeutic strategy for NSCLC, warranting further investigation into the interplay between probiotics, chemotherapy, and the gut microbiota.